JP2015524826A - Ｖｅｇｆｒ３阻害剤 - Google Patents
Ｖｅｇｆｒ３阻害剤 Download PDFInfo
- Publication number
- JP2015524826A JP2015524826A JP2015526836A JP2015526836A JP2015524826A JP 2015524826 A JP2015524826 A JP 2015524826A JP 2015526836 A JP2015526836 A JP 2015526836A JP 2015526836 A JP2015526836 A JP 2015526836A JP 2015524826 A JP2015524826 A JP 2015524826A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- group
- compound
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*N(*)C(C(C)C)=O Chemical compound C*N(*)C(C(C)C)=O 0.000 description 23
- KDTBEIPBHBHNOY-UHFFFAOYSA-N NC(C1(CC1)c1c(CCc(nc(nc2)Cl)c2Cl)cccc1)=O Chemical compound NC(C1(CC1)c1c(CCc(nc(nc2)Cl)c2Cl)cccc1)=O KDTBEIPBHBHNOY-UHFFFAOYSA-N 0.000 description 4
- MPTDKCBUARYSSY-UHFFFAOYSA-N CC(C(N)=O)c(cccc1)c1C#C Chemical compound CC(C(N)=O)c(cccc1)c1C#C MPTDKCBUARYSSY-UHFFFAOYSA-N 0.000 description 2
- LHJMGYGGMAYNQJ-UHFFFAOYSA-N CC(N)NC(NC)=N Chemical compound CC(N)NC(NC)=N LHJMGYGGMAYNQJ-UHFFFAOYSA-N 0.000 description 2
- LBGSWBJURUFGLR-UHFFFAOYSA-N C[n]1ncc(N)c1 Chemical compound C[n]1ncc(N)c1 LBGSWBJURUFGLR-UHFFFAOYSA-N 0.000 description 2
- JLTNZXKSAAMAFT-UHFFFAOYSA-N CC(C(N)=O)c(cccc1)c1C#C[Si](C)(C)C Chemical compound CC(C(N)=O)c(cccc1)c1C#C[Si](C)(C)C JLTNZXKSAAMAFT-UHFFFAOYSA-N 0.000 description 1
- RGUWUWISOULBHU-UHFFFAOYSA-N CC(C(N)=O)c(cccc1)c1C#Cc1c(C(F)(F)F)cnc(Nc(cc2)cnc2OC)n1 Chemical compound CC(C(N)=O)c(cccc1)c1C#Cc1c(C(F)(F)F)cnc(Nc(cc2)cnc2OC)n1 RGUWUWISOULBHU-UHFFFAOYSA-N 0.000 description 1
- HNIUQNOJWSUIQG-UHFFFAOYSA-N CC(C(N)=O)c(cccc1)c1I Chemical compound CC(C(N)=O)c(cccc1)c1I HNIUQNOJWSUIQG-UHFFFAOYSA-N 0.000 description 1
- MXIBXHRQUQYGTB-UHFFFAOYSA-N CC(C(N)=O)c1c(CCc2c(C(F)(F)F)cnc(Nc(cc3)cnc3OC)n2)cccc1 Chemical compound CC(C(N)=O)c1c(CCc2c(C(F)(F)F)cnc(Nc(cc3)cnc3OC)n2)cccc1 MXIBXHRQUQYGTB-UHFFFAOYSA-N 0.000 description 1
- YWVFNEJAHCAGQD-UHFFFAOYSA-N CC(C(N)=O)c1c(CCc2nc(Cl)ncc2Cl)cccc1 Chemical compound CC(C(N)=O)c1c(CCc2nc(Cl)ncc2Cl)cccc1 YWVFNEJAHCAGQD-UHFFFAOYSA-N 0.000 description 1
- GJDCNROAKOCYIQ-UHFFFAOYSA-N CC(C)(C)OC([n](c(C)c1)nc1N)=O Chemical compound CC(C)(C)OC([n](c(C)c1)nc1N)=O GJDCNROAKOCYIQ-UHFFFAOYSA-N 0.000 description 1
- XMDRIBPTIGVLOD-UHFFFAOYSA-N CC(C)(C)OC([n]1nc(C)cc1N)=O Chemical compound CC(C)(C)OC([n]1nc(C)cc1N)=O XMDRIBPTIGVLOD-UHFFFAOYSA-N 0.000 description 1
- FIBAJOZIOKKYHC-UHFFFAOYSA-N CC(C)(C)OC([n]1ncc(N)c1)=O Chemical compound CC(C)(C)OC([n]1ncc(N)c1)=O FIBAJOZIOKKYHC-UHFFFAOYSA-N 0.000 description 1
- UQUHQKVINDTPNE-UHFFFAOYSA-N CC(CC1)CCN1N Chemical compound CC(CC1)CCN1N UQUHQKVINDTPNE-UHFFFAOYSA-N 0.000 description 1
- FAQGMOSSSZPRGG-UHFFFAOYSA-N CCCC(CC1)CCC1c(cc1)ccc1Nc1ncc(C(F)(F)F)c(CCc2c(C3(CC3)C(N)=O)cccc2)n1 Chemical compound CCCC(CC1)CCC1c(cc1)ccc1Nc1ncc(C(F)(F)F)c(CCc2c(C3(CC3)C(N)=O)cccc2)n1 FAQGMOSSSZPRGG-UHFFFAOYSA-N 0.000 description 1
- KSIYIAJUQCMDOR-UHFFFAOYSA-N CN(CC1)CCC1c(cc1)ncc1Nc(nc1)nc(CCc2c(C3(CC3)C(N)=O)cccc2)c1Cl Chemical compound CN(CC1)CCC1c(cc1)ncc1Nc(nc1)nc(CCc2c(C3(CC3)C(N)=O)cccc2)c1Cl KSIYIAJUQCMDOR-UHFFFAOYSA-N 0.000 description 1
- UIHAKZQUZUYRHS-UHFFFAOYSA-N COC(C1(C(Cc(cc2)cc(C3(CC3)C(O)=O)c2Br)C1)c(cccc1)c1Br)=O Chemical compound COC(C1(C(Cc(cc2)cc(C3(CC3)C(O)=O)c2Br)C1)c(cccc1)c1Br)=O UIHAKZQUZUYRHS-UHFFFAOYSA-N 0.000 description 1
- KXFAWBQHWBJQNA-UHFFFAOYSA-N COC(C1(CC1)c(cccc1)c1C#C[Si+](C)(C)C)=O Chemical compound COC(C1(CC1)c(cccc1)c1C#C[Si+](C)(C)C)=O KXFAWBQHWBJQNA-UHFFFAOYSA-N 0.000 description 1
- UUVDJIWRSIJEBS-UHFFFAOYSA-N COc(cc1)ncc1N Chemical compound COc(cc1)ncc1N UUVDJIWRSIJEBS-UHFFFAOYSA-N 0.000 description 1
- DYEIAFSGCAVIRA-UHFFFAOYSA-N COc(cc1)ncc1Nc1nc(Cl)c(C(F)(F)F)cn1 Chemical compound COc(cc1)ncc1Nc1nc(Cl)c(C(F)(F)F)cn1 DYEIAFSGCAVIRA-UHFFFAOYSA-N 0.000 description 1
- WQAZWPJKTOEOQF-UHFFFAOYSA-N Cc1cc(Nc(nc2CCc3c(C4(CC4)C(N)=O)cccc3)ncc2Cl)n[nH]1 Chemical compound Cc1cc(Nc(nc2CCc3c(C4(CC4)C(N)=O)cccc3)ncc2Cl)n[nH]1 WQAZWPJKTOEOQF-UHFFFAOYSA-N 0.000 description 1
- IDRUEHMBFUJKAK-UHFFFAOYSA-N FC(c(c(Cl)n1)cnc1Cl)(F)F Chemical compound FC(c(c(Cl)n1)cnc1Cl)(F)F IDRUEHMBFUJKAK-UHFFFAOYSA-N 0.000 description 1
- YNPZQOCKZKZHEM-UHFFFAOYSA-N NC(C1(CC1)c1c(CCc(nc(Nc2cnc(C3CCNCC3)cc2)nc2)c2Cl)cccc1)=O Chemical compound NC(C1(CC1)c1c(CCc(nc(Nc2cnc(C3CCNCC3)cc2)nc2)c2Cl)cccc1)=O YNPZQOCKZKZHEM-UHFFFAOYSA-N 0.000 description 1
- YCIIZJUIBNPNED-UHFFFAOYSA-N NC(C1(CC1)c1c(CCc2c(C(F)(F)F)cnc(Nc3ccc(C4CCNCC4)cc3)n2)cccc1)=O Chemical compound NC(C1(CC1)c1c(CCc2c(C(F)(F)F)cnc(Nc3ccc(C4CCNCC4)cc3)n2)cccc1)=O YCIIZJUIBNPNED-UHFFFAOYSA-N 0.000 description 1
- IDBAAYPNWLPEBC-UHFFFAOYSA-N NC(C1(CC1)c1c(CCc2nc(Nc3c[nH]nc3)ncc2Cl)cccc1)=O Chemical compound NC(C1(CC1)c1c(CCc2nc(Nc3c[nH]nc3)ncc2Cl)cccc1)=O IDBAAYPNWLPEBC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261684202P | 2012-08-17 | 2012-08-17 | |
| US61/684,202 | 2012-08-17 | ||
| PCT/AU2013/000913 WO2014026243A1 (en) | 2012-08-17 | 2013-08-16 | Vegfr3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524826A true JP2015524826A (ja) | 2015-08-27 |
| JP2015524826A5 JP2015524826A5 (enExample) | 2016-10-06 |
Family
ID=50101126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526836A Pending JP2015524826A (ja) | 2012-08-17 | 2013-08-16 | Ｖｅｇｆｒ３阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20160009686A1 (enExample) |
| EP (1) | EP2885291A4 (enExample) |
| JP (1) | JP2015524826A (enExample) |
| CN (1) | CN104736533B (enExample) |
| AU (1) | AU2013302320A1 (enExample) |
| CA (1) | CA2882158A1 (enExample) |
| HK (1) | HK1209105A1 (enExample) |
| WO (1) | WO2014026243A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019536766A (ja) * | 2016-11-10 | 2019-12-19 | 浙江大学Ｚｈｅｊｉａｎｇ Ｕｎｉｖｅｒｓｉｔｙ | ２−置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882270A1 (en) | 2012-08-17 | 2014-02-20 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
| WO2015123722A1 (en) * | 2014-02-19 | 2015-08-27 | Bionomics Limited | Inhibitors |
| CN106588884B (zh) * | 2016-11-10 | 2019-04-09 | 浙江大学 | 2-多取代芳环-嘧啶类衍生物及制备和医药用途 |
| CA3086182A1 (en) * | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
| US11548908B2 (en) | 2017-12-29 | 2023-01-10 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| CN109942616A (zh) * | 2019-04-18 | 2019-06-28 | 广东工业大学 | 一种含炔基的芳基酰胺类衍生物及其制备方法和应用 |
| WO2023073148A1 (en) * | 2021-10-29 | 2023-05-04 | Janssen Pharmaceutica Nv | Vascular endothelial growth factor receptor 3 as biomarker for bace2 activity |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010539094A (ja) * | 2007-09-10 | 2010-12-16 | キュリス，インコーポレイテッド | 亜鉛結合部分を含むｖｅｇｆｒインヒビター |
| WO2012022408A1 (de) * | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate als fak inhibitoren |
| WO2012036919A2 (en) * | 2010-09-14 | 2012-03-22 | Glaxosmithkline Llc | Combination of braf and vegf inhibitors |
| JP2012511016A (ja) * | 2008-12-05 | 2012-05-17 | アボット・ラボラトリーズ | 癌の治療に使用するためのキナーゼ阻害剤としてのチエノ［３，２−ｃ］ピリジン誘導体 |
| JP2012526766A (ja) * | 2009-05-14 | 2012-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍性及び線維性疾患の処置における新規な併用療法 |
| JP5937111B2 (ja) * | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ | Ｆａｋ阻害剤 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| ES2284200T3 (es) | 1997-02-12 | 2007-11-01 | Electrophoretics Limited | Marcadores proteicos para cancer de pulmon y uso de los mismos. |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| PT1244647E (pt) | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
| HRP20020751B1 (hr) | 2000-02-15 | 2011-01-31 | Sugen | Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| JP4460292B2 (ja) | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
| WO2008008234A1 (en) * | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| WO2008076415A1 (en) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| MX2011004680A (es) | 2008-11-06 | 2011-05-25 | Astrazeneca Ab | Moduladores de beta amiloide. |
| WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
| DK2675794T3 (da) * | 2011-02-17 | 2019-05-06 | Cancer Therapeutics Crc Pty Ltd | Selektive fak-inhibitorer |
| KR101682417B1 (ko) | 2011-02-25 | 2016-12-06 | 주식회사유한양행 | 다이아미노피리미딘 유도체 및 그의 제조방법 |
| JP6226981B2 (ja) | 2012-07-17 | 2017-11-08 | サノフイ | 肝細胞癌を処置するためのｖｅｇｆｒ−３阻害剤の使用 |
| WO2014027199A1 (en) * | 2012-08-14 | 2014-02-20 | Cancer Therapeutics Crc Pty Ltd | Fak and flt3 inhibitors |
| CN103113355B (zh) | 2013-02-27 | 2014-08-13 | 无锡爱内特生物科技有限公司 | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 |
-
2013
- 2013-08-16 HK HK15109687.2A patent/HK1209105A1/xx unknown
- 2013-08-16 AU AU2013302320A patent/AU2013302320A1/en not_active Abandoned
- 2013-08-16 WO PCT/AU2013/000913 patent/WO2014026243A1/en not_active Ceased
- 2013-08-16 CN CN201380052158.7A patent/CN104736533B/zh not_active Expired - Fee Related
- 2013-08-16 EP EP13829265.1A patent/EP2885291A4/en not_active Withdrawn
- 2013-08-16 CA CA2882158A patent/CA2882158A1/en not_active Abandoned
- 2013-08-16 US US14/422,093 patent/US20160009686A1/en not_active Abandoned
- 2013-08-16 US US13/969,037 patent/US9238644B2/en not_active Expired - Fee Related
- 2013-08-16 JP JP2015526836A patent/JP2015524826A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010539094A (ja) * | 2007-09-10 | 2010-12-16 | キュリス，インコーポレイテッド | 亜鉛結合部分を含むｖｅｇｆｒインヒビター |
| JP2012511016A (ja) * | 2008-12-05 | 2012-05-17 | アボット・ラボラトリーズ | 癌の治療に使用するためのキナーゼ阻害剤としてのチエノ［３，２−ｃ］ピリジン誘導体 |
| JP2012526766A (ja) * | 2009-05-14 | 2012-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍性及び線維性疾患の処置における新規な併用療法 |
| WO2012022408A1 (de) * | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate als fak inhibitoren |
| WO2012036919A2 (en) * | 2010-09-14 | 2012-03-22 | Glaxosmithkline Llc | Combination of braf and vegf inhibitors |
| JP5937111B2 (ja) * | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ | Ｆａｋ阻害剤 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019536766A (ja) * | 2016-11-10 | 2019-12-19 | 浙江大学Ｚｈｅｊｉａｎｇ Ｕｎｉｖｅｒｓｉｔｙ | ２−置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104736533B (zh) | 2016-12-07 |
| WO2014026243A1 (en) | 2014-02-20 |
| HK1209105A1 (en) | 2016-03-24 |
| CN104736533A (zh) | 2015-06-24 |
| US20140073620A1 (en) | 2014-03-13 |
| US20160009686A1 (en) | 2016-01-14 |
| AU2013302320A1 (en) | 2015-02-26 |
| EP2885291A4 (en) | 2015-11-04 |
| EP2885291A1 (en) | 2015-06-24 |
| CA2882158A1 (en) | 2014-02-20 |
| US9238644B2 (en) | 2016-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5937111B2 (ja) | Ｆａｋ阻害剤 | |
| US9238644B2 (en) | VEGFR3 inhibitors | |
| CA2827172C (en) | Selective fak inhibitors | |
| JP2005533011A (ja) | ヒストンデアセチラーゼ阻害剤として有用なベンズアミド誘導体 | |
| US9266864B2 (en) | VEGFR3 inhibitors | |
| JP2016504289A (ja) | がん治療用のピリミジン−２，４−ジアミン誘導体 | |
| EP3426351A1 (en) | Benzopiperidine derivatives and their use in the treatment of cancer and hemoglobinopathies | |
| CN102656172B (zh) | 8-氧代二氢嘌呤衍生物 | |
| WO2014027199A1 (en) | Fak and flt3 inhibitors | |
| WO2015123722A1 (en) | Inhibitors | |
| HK40066516B (en) | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | |
| HK40066516A (en) | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150617 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160816 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160816 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170525 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170530 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180109 |